Partner Headlines - BMRN

  1. Sarepta Soars On New Hope For Muscular-Dystrophy Drug

    IBD
  2. Alexion's $8.4 Billion Synageva Buyout Spooks Street

    IBD
  3. BIOMARIN PHARMA

    IBD
  4. BioMarin Completes Rolling NDA Submission to FDA for Drisapersen ...

    Benzinga
  5. J.P. Morgan's 3 Biotechnology Picks

    GuruFocus
  6. What Evercore Is Watching At BioMarin Pharmaceutical

    Benzinga
  7. BioMarin To Report Revenue In-line With Consensus, Wedbush Says

    Benzinga
  8. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  9. Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' ...

    Benzinga
  10. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD
  11. BIOMARIN PHARMA

    IBD
  12. State Of The Union Lights Up Biotech

    Benzinga
  13. Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical

    Benzinga
  14. UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical ...

    Benzinga
  15. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  16. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD
  17. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD
  18. What Investors Are Looking For In NPS Pharmaceuticals Ahead Of ...

    Benzinga
  19. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
  20. UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical ...

    Benzinga
  21. FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion ...

    Benzinga
  22. BioMarin Will Report Breadth of Innovative Development Pipeline ...

    Benzinga
  23. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga
  24. BioMarin buying Prosensa

    IBD
  25. Trio Of Major Deals Disclosed

    IBD
  26. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly ...

    Benzinga
  27. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters ...

    Benzinga
  28. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire ...

    Benzinga
  29. Benzinga's Volume Movers

    Benzinga
  30. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  31. Stocks Hitting 52-Week Highs

    Benzinga
  32. Morning Market Movers

    Benzinga
  33. Stock Futures Trending Higher; Kate Spade Bags An Upgrade

    IBD
  34. BioMarin Pharmaceuticals To Acquire Prosensa

    Benzinga
  35. Benzinga's Top #PreMarket Gainers

    Benzinga
  36. US Stock Futures Up Ahead Of Economic Data

    Benzinga
  37. Stocks Hitting 52-Week Highs

    Benzinga
  38. Benzinga's Top Upgrades

    Benzinga
  39. Benzinga's M&A Chatter for Tuesday October 21, 2014

    Benzinga
  40. BioMarin Weathers The Storm

    Benzinga
  41. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  42. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD
  43. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga
  44. Benzinga's Top Upgrades

    Benzinga
  45. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  46. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, ...

    Benzinga
  47. Top Trending Tickers On StockTwits For February 18

    Benzinga
  48. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga
  49. You Can No Longer Ignore Biotech

    GuruFocus
  50. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  51. Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, ...

    Benzinga
  52. UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical ...

    Benzinga
  53. UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On ...

    Benzinga
  54. BioMarin Wins FDA Panel Vote, Cuts Deal With Myriad

    IBD
  55. Benzinga's Top #PreMarket Gainers

    Benzinga
  56. BioMarin Confirms FDA Panel Recommends Approval of Vimizim for ...

    Benzinga
  57. BioMarin Stock Trading Halted Today for FDA Endocrinologic and ...

    Benzinga
  58. Gilead Sciences Leads In Rising Short Interest Among Biotechs ...

    Benzinga
  59. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  60. BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA ...

    Benzinga
  61. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics ...

    Benzinga
  62. US Oncology, Biomarin Announce Collaboration to Launch PARP Inhibitor ...

    Benzinga
  63. Roche

    IBD
  64. BioMarin Announces 5 Poster Presentations on BMN 673 at AACR-NCI-EORTC ...

    Benzinga
  65. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga
  66. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  67. BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast ...

    Benzinga
  68. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, ...

    Benzinga
  69. Market Primer: Friday, September 20: US Markets Fall As Investors ...

    Benzinga
  70. Benzinga's M&A Chatter for Thursday September 19, 2013

    Benzinga
  71. Report: Roche Lines up $15B in Debt to Buy BioMarin

    FoxBusiness
  72. Benzinga's Volume Movers

    Benzinga
  73. Benzinga's Top Pre-Market Gainers

    Benzinga
  74. UPDATE: Stifel Downgrades BioMarin Pharmaceutical on Appropriate ...

    Benzinga
  75. Benzinga's Top Pre-Market Gainers

    Benzinga
  76. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    Benzinga
  77. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  78. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  79. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  80. UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

    Benzinga
  81. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  82. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  83. J.P. Morgan Reiterates Overweight Rating, $60 PT on BioMarin ...

    Benzinga
  84. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  85. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  86. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  87. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  88. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  89. UPDATE: Wedbush Reiterates BioMarin Pharmaceuticals at Neutral ...

    Benzinga
  90. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  91. BioMarin, Prestige Brands and Other Top Performing Health Care ...

    Benzinga
  92. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  93. Weekly Top Insider Sells? AAPL, GILD, BMRN, and PCLN

    GuruFocus
  94. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  95. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  96. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  97. Myriad Genetics Stock Hits High On Earnings Beat

    IBD
  98. Highs & Lows: BioMarin Pharmaceutical, Best Buy, and Skullcandy

    SchaeffersResearch
  99. BioMarin soars on drug data

    IBD
  100. Mid-Afternoon Market Update: Markets Rally, Vringo Jumps

    Benzinga
Trading Center